NCT00783289 - A Phase 2a Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Adults With Asthma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 14, 2008

Primary Completion Date

November 17, 2009

Study Completion Date

November 17, 2009

Conditions

Asthma

Interventions

OTHER

Placebo

Placebo matched to benralizumab (MEDI-563) injection subcutaneously on Day 0, 28, and 56.

BIOLOGICAL

Benralizumab 25 mg

Benralizumab (MEDI-563) injection 25 milligram (mg) subcutaneously on Day 0, 28, and 56.

BIOLOGICAL

Benralizumab 100 mg

Benralizumab (MEDI-563) injection 100 mg subcutaneously on Day 0, 28, and 56.

BIOLOGICAL

Benralizumab 200 mg

Benralizumab (MEDI-563) injection 200 mg subcutaneously on Day 0, 28, and 56.

Trial Locations (6)

Allergy Associates Research Center, Portland

Research Site, Encinitas

Research Site, Los Angeles

Research Site, Colorado Springs

Research Site, Wheaton

Research Site, Upland